The present invention relates to the prevention and/or treatment of metabolic disorders. In particular the present invention relates to preventing and/or treating metabolic disorders by modulating, in particular reducing the amount of enterobacteria in the gut. One embodiment of the present invention relates to the use of a primary composition comprising an agent that reduces the amount of enterobacteria in the gut for the preparation of a composition to treat or prevent metabolic disorders
